EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka

Agampodi Danushi Mendis Gunasekara, Sitaporn Youngkong, Thunyarat Anothaisintawee, Thitiya Dejthevaporn, Rohini Fernandopulle, Usa Chaikledkaew

Scientific Reports · 2024

DOI: 10.1038/s41598-024-67598-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Agampodi Danushi Mendis Gunasekara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy, Cost-Benefit Analysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Bill & Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to assess the cost-utility and budget impact of dual to single HER2 targeted neoadjuvant therapy for HER2-positive breast cancer in Sri Lanka. A five-health state Markov model with lifetime horizon was used to assess the cost-utility of neoadjuvant trastuzumab (T) plus pertuzumab (P) or lapatinib (L) compared to single therapy of T with chemotherapy (C), in public healthcare system and societal perspectives. Input parameters were estimated using local data, network meta-analysis, published reports and literature. Costs were adjusted to year 2021 (1USD = LKR194.78). Five-year budget impact for public healthcare system was assessed. Incremental cost-effectiveness ratios in societal perspective for neoadjuvantLTC plus adjuvantT (strategy 3), neoadjuvantPTC plus adjuvantT (strategy 2), neoadjuvantLTC plus adjuvantLT (strategy 5), and neoadjuvantPTC plus adjuvantPT (strategy 4) compared to neoadjuvantTC plus adjuvantT (strategy 1) were USD2716, USD5600, USD6878, and USD12127 per QALY gained, respectively. One GDP per-capita (USD3815) was considered as the cost-effectiveness threshold for the analysis. Even though only the ICER for strategy 3 was cost-effective, uncertainty of efficacy parameter was revealed. For strategy 2 neoadjuvant PTC plus adjuvant T, a 25% reduction of neoadjuvant regimen cost was required to be cost effective for use in early HER2 positive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyCost-Benefit AnalysisTrastuzumabLapatinibHumansFemaleSri LankaAntineoplastic Combined Chemotherapy ProtocolsMarkov ChainsAntibodies, Monoclonal, HumanizedQuality-Adjusted Life YearsBudgetsMiddle Aged

Stichwörter der Autor:innen

Cost-utility analysisHER2 positive breast cancerNeoadjuvantTargeted therapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabLapatinibAntibodies, Monoclonal, HumanizedpertuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
  • Department of Paraclinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University, Ratmalana, Sri Lanka.
  • Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand. sitaporn.you@mahidol.edu.
  • Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudhaya Rd., Phayathai, Ratchathevi, Bangkok, Thailand. sitaporn.you@mahidol.edu.
  • Department of Family Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Medical Oncology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Förderung

  • The Bill & Melinda Gates Foundation

Zitieren

APA

Gunasekara, A. D. M., Youngkong, S., Anothaisintawee, T., Dejthevaporn, T., Fernandopulle, R., & Chaikledkaew, U. (2024). Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka. Scientific Reports. https://doi.org/10.1038/s41598-024-67598-2

Vancouver

Gunasekara ADM, Youngkong S, Anothaisintawee T, Dejthevaporn T, Fernandopulle R, Chaikledkaew U. Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka. Scientific Reports. 2024. doi:10.1038/s41598-024-67598-2

BibTeX
@article{Gunasekara2024,
  author = {Gunasekara, Agampodi Danushi Mendis and Youngkong, Sitaporn and Anothaisintawee, Thunyarat and Dejthevaporn, Thitiya and Fernandopulle, Rohini and Chaikledkaew, Usa},
  title = {Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka},
  journal = {Scientific Reports},
  year = {2024},
  doi = {10.1038/s41598-024-67598-2}
}
Kostenlos starten →